C. Groetzinger

Is the neuropeptide PEN a ligand of GPR83?

This study investigates whether PEN is a ligand of GPR83 and finds no evidence supporting this claim through multiple assays.

Secretin receptor as a target in gastrointestinal cancer: expression analysis and ligand development

This study analyzes SCTR expression in cancers and identifies key residues for secretin binding and activation, aiming to develop stable analogs for imaging and therapy.

A chemerin peptide analog stimulates tumor growth in two xenograft mouse models of human colorectal carcinoma

This study shows that a chemerin peptide analog promotes tumor growth in colorectal cancer xenograft models but not in vitro proliferation or migration.

SPECT/CT imaging, biodistribution and radiation dosimetry of a 177Lu-DOTA-integrin αvβ6 cystine knot peptide in a pancreatic cancer xenograft model

This study evaluates a 177Lu-labeled integrin αvβ6-targeting knottin peptide for imaging and therapy of pancreatic cancer using xenograft models, showing high tumor accumulation and moderate kidney uptake.

mTOR inhibitors as radiosensitizers in neuroendocrine neoplasms

This study investigates the radiosensitizing effect of mTOR inhibitors in neuroendocrine neoplasms using cell line assays and finds additive radiosensitization with moderate overall effect.

AGTR1 is overexpressed in neuroendocrine neoplasms, regulates secretion and may serve as a target for molecular imaging and therapy

This study identifies AGTR1 as an overexpressed target in neuroendocrine neoplasms, showing its role in secretion and potential for imaging and therapy.

CMKLR1-targeting peptide tracers for PET/MR imaging of breast cancer

This paper develops CMKLR1-targeting peptide tracers for PET/MR imaging of breast cancer, showing high specificity and affinity in vivo.

Increasing molar activity by HPLC purification improves 68Ga-DOTA-NAPamide tumor accumulation in a B16/F1 melanoma xenograft model

This study shows that HPLC purification of 68Ga-DOTA-NAPamide increases tumor uptake in B16/F1 melanoma xenografts by removing unlabeled peptide, enhancing molar activity and specific binding.